Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK/PD of RS-C1001 in Healthy Chinese Subjects
NCT06669429Phase 1Recruiting
- Sponsor
- Peking University First Hospital
- Start
- Sep 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of RS-C1001 in dyslipidemia (10 cohorts), sponsored by Peking University First Hospital. Primary endpoints: Numbers of participants with Adverse Events (AEs) or Serious Adverse Events (SAEs), Numbers of participants with clinical laboratory tests abnormalities and 3 more. Started Sep 2024; status: recruiting.
02
Drugs
RS-C1001
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT06669429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06669429.